Sunil Suhas Solomon, MBBS PhD MPH is a Professor of Medicine and Epidemiology in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine, USA. He is also the Co-Director of the Johns Hopkins Center for Infectious Diseases in India. He completed his medical training at the Sri Ramachandra Medical University in Chennai, India and received a Master of Public Health (MPH) and a doctorate in Epidemiology (PhD) from the Johns Hopkins University, USA. Dr. Solomon has been elected into the Phi Beta Kappa honors society for academic excellence and the Delta Omega Public Health honors society. His research is primarily focused on the epidemiology, clinical management and access to services for HIV and viral hepatitis among vulnerable populations such as people who inject drugs (PWID) and men who have sex with men (MSM), primarily from low and middle-income country settings. He has over 150 peer-reviewed original research publications in several highly ranked journals. He serves as a Deputy Editor of the Journal of the International AIDS Society and an Associate Editor of Drug and Alcohol Dependence. He is also a member of the PWID and ART technical resource group of the National AIDS Control Organization. He currently serves on the Scientific Agenda Steering Committee (SASC) of the AIDS Clinical Trials Group (ACTG) and Substance Use Scientific Committee (SUSC) of the HIV Prevention Trials Network (HPTN), two of the largest NIH-funded global networks that conduct research in the fields of HIV, viral hepatitis, TB and COVID.
In 2015, he was one of the first recipients of the Avenir award, a Director’s award from the National Institutes of Drug Abuse, USA aimed at identifying individuals who propose high impact research and who show promise of being tomorrow's leaders in the field of drug abuse and HIV. He also served as the Protocol Chair of ACTG A5360 (MINMON) a ground-breaking global trial on the simplification of HCV treatment delivery and currently serves as the Protocol Chair of HPTN 103/PURPOSE-4, the first trial of long acting antiretrovirals for PrEP among people who inject drugs. He was also awarded US $35 million in 2019 from PEPFAR/USAID to provide technical assistance to the National AIDS Program in India.
User Profile Bio
